GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immatics NV (FRA:4A3) » Definitions » Valuation Rank

Immatics NV (FRA:4A3) Valuation Rank


View and export this data going back to 2020. Start your Free Trial

What is Immatics NV Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Immatics NV Valuation Rank Related Terms

Thank you for viewing the detailed overview of Immatics NV's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Immatics NV (FRA:4A3) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immatics NV (FRA:4A3) » Definitions » Valuation Rank
Comparable Companies
NAMS VERV SANA KURA VRDN PRME AMAM KYMR ADPT RGNX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
IMTX:USA
Address
Paul-Ehrlich-Strasse 15, Tubingen, BW, DEU, 72076
Website
https://www.immatics.com
Immatics NV is a biotechnology company that is engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.